Published in Curr Opin Lipidol on August 01, 2007
Effects of Short-term Diet on HDL Composition and Function | NCT03205254
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
Inflammation impairs reverse cholesterol transport in vivo. Circulation (2009) 2.86
In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int (2009) 2.09
Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol (2010) 1.79
High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem (2010) 1.69
Prenatal exposure to cigarette smoke induces diet- and sex-dependent dyslipidemia and weight gain in adult murine offspring. Environ Health Perspect (2009) 1.57
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum (2009) 1.48
HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol (2010) 1.32
Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol (2012) 1.27
High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem (2010) 1.19
Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women. Menopause (2011) 1.19
A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res (2011) 1.17
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2008) 1.12
Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol (2010) 1.11
Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol (2014) 1.04
Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice. J Lipid Res (2013) 1.02
Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response. Cholesterol (2010) 1.02
Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem (2010) 1.01
Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm (2012) 0.99
HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS One (2012) 0.95
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis (2014) 0.91
Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study. Atherosclerosis (2013) 0.91
HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients. J Am Soc Nephrol (2015) 0.90
Oxidative mechanisms and atherothrombotic cardiovascular disease. Drug Discov Today Ther Strateg (2008) 0.90
Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol (2013) 0.90
Interaction of HDL cholesterol concentrations on the relationship between physical function and inflammation in community-dwelling older persons. Age Ageing (2009) 0.88
A systems genetic analysis of high density lipoprotein metabolism and network preservation across mouse models. Biochim Biophys Acta (2011) 0.88
Association of serum uric acid and coronary artery disease in premenopausal women. PLoS One (2014) 0.85
The role of a murine transplantation model of atherosclerosis regression in drug discovery. Curr Opin Investig Drugs (2009) 0.82
HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol (2015) 0.82
Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels. PLoS One (2013) 0.81
High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis (2016) 0.80
Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis (2008) 0.80
Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation. Int J Inflam (2012) 0.80
Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest (2015) 0.78
Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes. Int J Endocrinol (2014) 0.77
Glycomic analysis of high density lipoprotein shows a highly sialylated particle. J Proteome Res (2014) 0.77
Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children. J Clin Cell Immunol (2016) 0.75
Lipid abnormalities in patients with Rheumatoid Arthritis. Pak J Med Sci (2017) 0.75
Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA. J Lipid Res (2016) 0.75
Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep (2017) 0.75
Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PLoS One (2012) 0.75
Association between two common polymorphisms (single nucleotide polymorphism -250G/A and -514C/T) of the hepatic lipase gene and coronary artery disease in type 2 diabetic patients. Adv Biomed Res (2016) 0.75
Investigation of Metabolic Factors Associated with eGFR Decline Over 1 Year in a Japanese Population without CKD. J Atheroscler Thromb (2017) 0.75
Paraoxonase (PON1) activity in patients with subclinical thoracic aortic atherosclerosis. Int J Cardiovasc Imaging (2014) 0.75
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol (2005) 4.26
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation (2009) 3.43
Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J (2008) 3.25
Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol (2012) 3.24
Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol (2004) 3.08
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07
Use of aldosterone antagonists in heart failure. JAMA (2009) 3.00
Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell (2003) 2.99
Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol (2002) 2.97
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (2006) 2.90
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol (2010) 2.86
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J (2007) 2.80
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail (2007) 2.75
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res (2004) 2.72
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol (2005) 2.71
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol (2011) 2.60
Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol (2006) 2.59
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. Circulation (2010) 2.53
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47
Cardiac troponin and outcome in acute heart failure. N Engl J Med (2008) 2.41
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 2.33
Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation (2010) 2.32
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27
Sex differences in medical care and early death after acute myocardial infarction. Circulation (2008) 2.17
Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA (2013) 2.17
Four-variable risk model in men and women with heart failure. Circ Heart Fail (2013) 2.14
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol (2009) 2.14
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol (2005) 2.11
An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J (2006) 2.11
In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int (2009) 2.09
Visual assessment of brain magnetic resonance imaging detects injury to cognitive regulatory sites in patients with heart failure. J Card Fail (2013) 2.07
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J (2008) 2.06
Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol (2007) 2.06
B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. Am Heart J (2012) 2.04
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.99
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail (2011) 1.99
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res (2007) 1.96
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension (2013) 1.95
Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. Circ Heart Fail (2009) 1.95
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol (2011) 1.92
Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation (2003) 1.90
Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. J Card Fail (2011) 1.90
The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med (2009) 1.89
Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol (2009) 1.88
A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. Circ Cardiovasc Qual Outcomes (2009) 1.86
Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab (2006) 1.83
Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation (2008) 1.81
Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res (2007) 1.81
Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol (2009) 1.81
Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg (2003) 1.78
Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. Stroke (2014) 1.76
The role of dysfunctional HDL in atherosclerosis. J Lipid Res (2008) 1.73
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A (2010) 1.71
Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail (2009) 1.70
Association of patient case-mix adjustment, hospital process performance rankings, and eligibility for financial incentives. JAMA (2008) 1.69
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol (2003) 1.67
The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart (2010) 1.67
Regional brain gray matter loss in heart failure. J Appl Physiol (1985) (2003) 1.67
Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. Circulation (2010) 1.66
American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers. Circulation (2013) 1.66
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol (2012) 1.65
Payment source, quality of care, and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol (2011) 1.65